Macular Telangiectasia Therapeutics Market Size, Share, and Industry Analysis, By Product (ENCELTO and Others), By Type (Type 2, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Others), and Regional Forecast, 2026-2034

The global macular telangiectasia therapeutics market is witnessing significant growth due to the rise in the prevalence of macular telangiectasia (MacTel). People with chronic diseases, such as diabetes, hypertension, retinal vein occlusion, etc., are more vulnerable to developing macular telangiectasia. Additionally, the increase in demand for effective treatment and high research and development activities also supports the growth of the market. 

• For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in October 2022, the Beaver Dam Eye Study reported the prevalence of macular telangiectasia was 0.1% in 4790 individuals aged between 43 to 86 years.

Macular telangiectasia (MacTel) is a very rare eye disease that affects the macula, a central part of the retina. The abnormalities in the capillaries (tiny blood vessels) around the fovea lead to vision loss, particularly for tasks such as reading and recognizing faces.

Macular Telangiectasia Therapeutics Market Driver

New Product Launches to Drive the Market Growth

The market expansion is expected to be driven by an increase in product launches. Till now off-label drugs and treatments have been used to cure macular telangiectasia, but recently, only one drug has been approved for the treatment of macular telangiectasia. Such new product launches are expected to increase the availability of effective treatment options, in turn, boosting the market growth in the upcoming years.

• For instance, in March 2025, the U.S. FDA approved Encelto (revakinagene taroretcel-lwey), a cell-based gene therapy for the treatment of type 2 macular telangiectasia (MacTel) in adults.

Prevalence of Diabetic Retinopathy, By Key Regions 2021

According to the data published in the journal Ophthalmology in November 2021, the prevalence of diabetic retinopathy is higher in Africa, followed by the Caribbean and Central America. People living with diabetes are more prone to developing macular telangiectasia disease. 

Macular Telangiectasia Therapeutics Market Restraint

High Development Cost May Limit the Market Growth

The high development cost of macular telangiectasia treatment may limit the market growth. Macular telangiectasia is a rare disease, and it is associated with high costs, such as research, development, and production of new drugs, leading to limit R&D activities in low-middle economic countries. 

• For instance, according to the data published by the National Centre for Biotechnology Information in November 2023, high development and production costs are the main hurdles, as long research and development timelines were required to develop macro telangiectasia treatment.

Macular Telangiectasia Therapeutics Market Opportunity

Novel Therapies May Offer Potential Opportunity in Future

In recent years, due to technological advancements, there has been a rise in the development of novel therapies, such as anti-VEGF and laser-based approaches, which are anticipated to offer lucrative growth opportunities in the future. The robust pipeline of advanced products based on anti-VEGF drugs and innovations by key market players also enhances the treatment regimen of this disease, in turn propelling the market growth in the coming years. 

• For instance, Oxurion NV is actively involved in the development of a combination of THR-317 and ranibizumab for the treatment of macular telangiectasia type 1.

Key Insights

The report covers the following key insights:

• Prevalence of Macular Telangiectasia, By Key Countries
• New Product Launches/ Approvals, By Key Players
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Product

By product, the market is divided into ENCELTO and others.

The ENCELTO segment held a substantial share of the market. This is only the U.S. FDA-approved drug aim to treat macular telangiectasia disease, which drives the segment growth. ENCELTO is a unique encapsulated cell therapy (ECT), and it’s a novel treatment option that provides long-term delivery of therapeutic proteins to the retina.

• For instance, in November 2022, Neurotech Pharmaceuticals, Inc. announced a positive result of a phase 3 clinical trial of investigational encapsulated cell therapy (ECT) for the treatment of type 2 MacTel disease.

Analysis by Type

The type segment is classified into type 2 and others. The type 2 segment is expected to grow significantly during the forecast period. This is due to the rise in the prevalence of type 2 macular telangiectasia. Additionally, ENCELTO, the only approved therapy for macular telangiectasia, is used to treat type 2 MacTel, which supports the segment growth during the forecast period. 

• For instance, according to the article published by the International Journal of Retina and Vitreous in August 2023, based on the hospital study, among all the participated MacTel patients, 1.77% of patients are young with type 2 disease, and their age is less than 40 years. The prevalence of macular telangiectasia type 2 disease is higher in females and diabetic patients.

Analysis by Distribution Channel

Based on the distribution channel, the market is classified into hospital pharmacies, specialty pharmacies, and others. Specialty pharmacies held a significant share of the macular telangiectasia therapeutics market in 2024. This is due to the fact that they provide patient-specific care, and they can manage complex treatment regimens. Additionally, the companies are collaborating with the specialty pharmacies for their product distribution.

• For instance, according to the data published by Anton Health, in May 2025, Neurotech Pharmaceuticals, Inc. selected Orsini Specialty Pharmacy as a specialty pharmacy partner for the distribution of Encelto (revakinagene taroretcel-lwey).

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a significant share of the global macular telangiectasia therapeutics market in 2024. The region has a high prevalence of macular telangiectasia, which drives the growth of the market. To treat this disease, only one drug is approved, and its manufacturing company is based in this region, which further support the market growth. Additionally, the advanced healthcare facilities and high research and development activities are leading to a boost in the market growth in this region. 

• For instance,Prevent Blindness, a voluntary organization dedicated to fighting blindness, created a Facebook group for people with macular telangiectasia to connect with others who understand MacTel disease. This type of initiative may support the market growth.

Europe has a considerable share of the macular telangiectasia therapeutics market. The growth of the region is attributed to the high adoption rate for new drugs. Additionally, government support and high investment in research and development activities also boost the market growth in the upcoming years.

The Asia Pacific region is the fastest-growing region in the global macular telangiectasia therapeutics market, driven by the rising prevalence and awareness of macular telangiectasia. 

Key Players Covered

The global macular telangiectasia therapeutics market is consolidated with a few key players. The report includes the profiles of the following key players:

• Neurotech Pharmaceuticals (U.S.)
• BioInvent International AB (Sweden)
• Oxurion NV (Belgium)
• Regeneron Pharmaceuticals Inc. (U.S.)

Key Industry Developments

• In April 2019, Oxurion NV announced its phase 2 trial full enrolment for the evaluation of efficacy and safety of the combination of THR-317 and ranibizumab, for the treatment of macular telangiectasia type 1.
• In September 2018, Oxurion with BioInvent International AB, enrolled the first patient in the phase 2 clinical study to evaluate the efficacy and safety of THR-317 for the treatment of MacTel type 1.